CLAIMS

1. Use of a VEGF antagonist in the manufacture of a medicament for treatment of moderately severe to severe nonproliferative diabetic retinopathy in a patient in need of such treatment, wherein the patient does not suffer from center involved diabetic macular edema, the treatment comprising, to be administered by intravitreal injection, to an eye of the patient, 5 monthly doses of the VEGF antagonist followed by one or more secondary doses every 8 weeks of about 2 mg of the VEGF antagonist, wherein the VEGF antagonist is aflibercept.

2. The use of the VEGF antagonist of claim 1, wherein:

(a) the patient suffers from nonproliferative diabetic retinopathy which is characterized by a Diabetic Retinopathy Severity Scale level of 47 or 53;

(b) the patient has a baseline best-corrected visual acuity (BCVA) ETDRS letter score of at least 69; and

(c) vision of the patient is characterized by a Snellen visual acuity of 20/40.

3. The use of the VEGF antagonist of any one of the preceding claims, wherein:

(a) the patient is human; or

(b) the patient is a human 18 years of age or older.

4. The use of the VEGF antagonist of any one of the preceding claims, wherein the patient does not suffer from one or more conditions selected from the group consisting of:

(a) retinal neovascularization;

(b) anterior segment neovascularization (ASNV);

(c) vitreous hemorrhage; and

(d) tractional retinal detachment.

5. The use of the VEGF antagonist of any one of the preceding claims, wherein the patient has one or more conditions selected from the group consisting of:

(a) diabetes;

(b) a hemoglobin A1c of about 8.5;

(c) an ETDRS BCVA score of 82;

(d) a central retinal thickness of about 247 μm;

(e) a diabetic retinopathy severity score of 47 or 53; and

(f) an age of about 56 years.